AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

HIKMA Pharmaceuticals PLC

Major Shareholding Notification Oct 1, 2025

4841_rns_2025-10-01_cfb2b110-41a5-42bf-93c0-8bc4ea941967.html

Major Shareholding Notification

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 6481B

Hikma Pharmaceuticals Plc

01 October 2025

Hikma Pharmaceuticals PLC

Block Listing Six Monthly Return

Date: 1 October 2025

Name of applicant: Hikma Pharmaceuticals PLC
Name of schemes: Hikma Pharmaceuticals PLC 2018 Management Incentive Plan ("MIP") and Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan ("EIP")
Period of return From: 1 April 2025 To: 30 September 2025
Balance of unallotted securities under scheme(s) from previous return: 311,430 Ordinary Shares of 10 pence
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 0 Ordinary Shares of 10 pence
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 0 Ordinary Shares of 10 pence
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 311,430 Ordinary Shares of 10 pence
Name of contact: Helen Middlemist
Telephone number of contact: +44(0)20 7399 2760

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY)

(LEI: 549300BNS685UXH4JI75)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLRUPGACUUPAGUG

Talk to a Data Expert

Have a question? We'll get back to you promptly.